FIELD: medicine, pharmaceutics.
SUBSTANCE: invention relates to field of cellular molecular biology and represents application of 3-bromo-fascaplysine as medication which inhibits activity of p53 nuclear transcription factor and inducing activity of AP-1 nuclear transcription factor.
EFFECT: invention ensures extension of arsenal of medications which inhibit activity of p53 nuclear transcription factor and induce activity of AP-1 nuclear transcription factor.
2 dwg
| Title | Year | Author | Number |
|---|---|---|---|
| AGENT PREVENTING MAMMAL NORMAL CELL TRANSFORMATION IN MALIGNANT CELLS | 2010 |
|
RU2429839C1 |
| GLYCOSIDE DERIVATIVES OF 1,2-DITHIOL-3-THIONE OR 1,2-DITHIOL-3-ONE AND PHARMACEUTICAL PRODUCTS BASED ON THEM | 2013 |
|
RU2534525C9 |
| AGENT PREVENTING MAMMAL NORMAL CELL TRANSFORMATION IN MALIGNANT CELLS | 2010 |
|
RU2429840C1 |
| THERAPEUTIC QUINONES | 2005 |
|
RU2411229C2 |
| ANTICANCER DRUG | 2009 |
|
RU2414920C1 |
| METHOD OF USING 4-((5,10-DIMETHYL-6-OXO-6,10-DIHYDRO-5H-PYRIMIDO[5,4-b]THIENO[3,2-e][1,4]DIAZEPIN-2-YL)AMINO)BENZENESULFONAMIDE (XMU-MP-1) TO INHIBIT GROWTH OF BURKITT'S LYMPHOMA CELLS | 2023 |
|
RU2814013C1 |
| TORK PROTEIN KINASE INHIBITOR WITH DIRECTED CHEMOPREVENTIVE EFFECT IN VITRO | 2014 |
|
RU2566268C1 |
| METHOD FOR ENHANCEMENT OF PROLIFERATIVE ACTIVITY OF MARINE INVERTEBRATES | 2002 |
|
RU2205873C1 |
| PIGAS CELL LINE CONTAINING STAT-1 TRANSCRIPTION FACTOR BINDING SITE STABLE-INTEGRATED IN GENOME | 2015 |
|
RU2619643C1 |
| METHOD FOR DETERMINING NON-SMALL CELLS LUNG CANCER SENSITIVITY TO PREPARATIONS REACTIVATING PROTEIN p53 | 2012 |
|
RU2509808C1 |
